A Real-world Observational Clinical Study Aims to Assess the Consistency of Clinical Efficacy in Gastric Cancer Treatment and Drug Susceptibility Outcomes Using a Novel Drug Susceptibility Testing Method
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Gastric Cancer
- Sponsor
- Funan Liu
- Enrollment
- 104
- Locations
- 1
- Primary Endpoint
- Specificity
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
The study is a real-world observational clinical study. Patients diagnosed as gastric cancer through histopathology were screened and enrolled. Before anti-tumor treatment, gastroscopy biopsy tissue specimens, surgical specimens, and malignant pleural effusion or ascites specimens, etc. are collected. The investigators will perform a drug sensitivity testing based on a novel drug susceptibility testing method to test the commonly used anti-tumor treatment regimens. Patients were given conventional anti-tumor treatment according to the medical judgment of the doctors. Finally, the investigator will evaluate the consistency of clinical efficacy in gastric cancer treatment and drug susceptibility outcomes.
Investigators
Funan Liu
professor
China Medical University, China
Eligibility Criteria
Inclusion Criteria
- •Male or female, aged ≥ 18 and ≤80;
- •Patients with gastric cancer diagnosed by histopathology;
- •Patients who need neoadjuvant treatment; adjuvant therapy after radical surgery or palliative treatment;
- •Fresh tumor tissue specimens or malignant pleural effusion or ascites can be obtained;
- •Patients who sign the informed consent form, and are able to comply with the study period treatment process.
Exclusion Criteria
- •Inability to follow the research protocol;
- •Inability to obtain relevant fresh specimens by biopsy/surgery/puncture;
- •Concomitant contraindications to chemotherapy;
- •pregnant or lactating women;
- •Patients deemed inappropriate by investigators.
Outcomes
Primary Outcomes
Specificity
Time Frame: Through study completion, an average of 1 year
Cases in which drug susceptibility results are resistance to the antineoplastic regimen as a percentage of the cases that are ineffective in clinical evaluation
Disease-free survival
Time Frame: From date of surgery until the date of first documented recurrence，up to 3 years
An Indicator of efficacy of postoperative adjuvant therapy
Sensitivity
Time Frame: Through study completion, an average of 1 year
Cases in which drug susceptibility results are sensitive to the antineoplastic regimen as a percentage of the cases that are effective in clinical evaluation